Pembrolizumab for the treatment of Progressive Multifocal Leukoencephalopathy (PML) in a patient with AIDS: A case report and literature review
Open Access
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Tratamiento con pembrolizumab en paciente con infección por virus de la inmunodeficiencia humana y leucoencefalopatía multifocal progresivaEnfermedades Infecciosas y Microbiología Clínica, 2020
- Stabilization of Progressive Multifocal Leukoencephalopathy After Pembrolizumab TreatmentThe Neurohospitalist, 2020
- Ineffective treatment of PML with pembrolizumabNeurology Neuroimmunology & Neuroinflammation, 2019
- Pembrolizumab for progressive multifocal leukoencephalopathy due to primary immunodeficiencyNeurology Neuroimmunology & Neuroinflammation, 2019
- Progressive multifocal leukoencephalopathy and anti‐CD20 monoclonal antibodies: What do we know after 20 years of rituximabReviews in Medical Virology, 2019
- Treatment of Progressive Multifocal Leukoencephalopathy with PembrolizumabNew England Journal of Medicine, 2019
- Pembrolizumab Treatment for Progressive Multifocal LeukoencephalopathyNew England Journal of Medicine, 2019
- Progressive Multifocal Leukoencephalopathy and Monoclonal AntibodiesCancer Control, 2017
- Increased Program Cell Death–1 Expression on T Lymphocytes of Patients With Progressive Multifocal LeukoencephalopathyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2012
- Identification of PD-1 as a Unique Marker for Failing Immune Reconstitution in HIV-1–Infected Patients on TreatmentJAIDS Journal of Acquired Immune Deficiency Syndromes, 2011